TMARKETVIEW_20050228.2211-E1-10	ORG 661 667	target
TMARKETVIEW_20050228.2211-E1-11	ORG 849 869	King Pharmaceuticals
TMARKETVIEW_20050228.2211-E1-12	ORG 670 690	King Pharmaceuticals
TMARKETVIEW_20050228.2211-E3-1	PER 110 113	You
TMARKETVIEW_20050228.2211-E4-4	PER 794 797	him
TMARKETVIEW_20050228.2211-E4-7	PER 884 886	he
TMARKETVIEW_20050228.2211-E4-8	PER 925 928	his
TMARKETVIEW_20050228.2211-E4-13	PER 123 125	he
TMARKETVIEW_20050228.2211-E4-16	PER 179 189	Carl Icahn
TMARKETVIEW_20050228.2211-E4-19	PER 268 270	he
TMARKETVIEW_20050228.2211-E4-22	PER 319 322	his
TMARKETVIEW_20050228.2211-E4-25	PER 422 425	him
TMARKETVIEW_20050228.2211-E4-26	PER 434 436	he
TMARKETVIEW_20050228.2211-E4-28	PER 615 617	he
TMARKETVIEW_20050228.2211-E4-30	PER 693 695	he
TMARKETVIEW_20050228.2211-E5-14	ORG 147 158	Blockbuster
TMARKETVIEW_20050228.2211-E6-15	ORG 163 172	Hollywood
TMARKETVIEW_20050228.2211-E7-2	ORG 739 743	they
TMARKETVIEW_20050228.2211-E7-3	ORG 781 786	Mylan
TMARKETVIEW_20050228.2211-E7-5	ORG 803 807	they
TMARKETVIEW_20050228.2211-E7-17	ORG 216 226	Mylan labs
TMARKETVIEW_20050228.2211-E7-20	ORG 298 305	company
TMARKETVIEW_20050228.2211-E7-29	ORG 640 645	Mylan
TMARKETVIEW_20050228.2211-E8-6	PER 81 86	Byrne
TMARKETVIEW_20050228.2211-E8-18	PER 229 230	I
TMARKETVIEW_20050228.2211-E9-21	PER 327 332	board
TMARKETVIEW_20050228.2211-E10-23	PER 344 354	management
TMARKETVIEW_20050228.2211-E10-24	PER 412 416	they
TMARKETVIEW_20050228.2211-E11-27	PER 507 515	opponent
RMARKETVIEW_20050228.2211-R1-1	PER-SOC Arg1:TMARKETVIEW_20050228.2211-E4-22 Arg2:TMARKETVIEW_20050228.2211-E9-21
